Director of Shandong Jincheng Pharmaceutical Group investigated for suspected stock market manipulation. Q1 performance just turned around according to announcement.
On the evening of today, Shandong Jincheng Pharmaceutical Group announced that its actual controller and chairman, Zhao Yeqing, was under investigation for suspected illegal acts of market manipulation by the China Securities Regulatory Commission. Zhao Yeqing has been the chairman of Jincheng Pharmaceutical Group for 13 years. The last time he appeared in public was at the 3rd China Pharmaceutical and Chemical Conference two days ago. In Q1 of 2024, Jincheng Pharmaceutical Group has shown a good trend of reversing last year's poor performance.
Due to lower caffeine prices, CSPC Innovation Pharmaceutical's Q2 performance continued the downward trend from Q1. | Interpretations
Due to factors such as the decline in caffeine prices, CSPC Innovation Pharmaceutical's revenue and net income have both declined. Several pipelines in CSPC Innovation Pharmaceutical have made progress, and Enracuab monoclonal antibody has been conditionally approved for listing in June of this year. In order to enhance the industrialization capability of monoclonal antibody and ADCs, the company announced that CSPC Biotech will invest in the construction of two production line projects.
Hengrui received an FDA warning letter | Jianzhi Research
A problem that should not have been present arose from a leader. Following the June FORM483 incident, Hengrui has one more opportunity to rectify the issue.
Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research
The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.
Hengrui's FORM 483 is not that simple | Jianzhi Research
According to the FDA website, Hengrui's January on-site inspection has entered the OAI phase, which means that the FDA is not satisfied with the company's first-stage response and corrective actions, and has made a formal regulatory decision. However, it should be emphasized that Hengrui still has the opportunity to submit rectification measures before further regulatory measures are taken. And this on-site inspection has nothing to do with the dual AI therapy going global.
Robinhood CEO Says Exchange Is Ready For Roaring Kitty Livestream Surge: 'We Are Prepared' For GameStop Frenzy